Objective: This study evaluated the tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in patients with COPD. Methods: This double-blind, placebo-controlled study (NCT00629239) randomised patients with moderate to severe COPD to AZD4818 300 mg or placebo twice daily via Turbuhaler Ò for 4 weeks. Safety, lung function, functional capacity and health status measures were measured. Plasma concentrations of AZD4818 were measured after the first dose and after 2 and 4 weeks' treatment. Results: Sixty-five patients (47 male; median age 65.6 years) received AZD4818 (n Z 33) or placebo (n Z 32). There was no statistically significant difference between AZD4818 and placebo in change from baseline to endpoint for FEV 1 (AZD4818eplacebo: 0.026 L, p Z 0.69), morning PEF (À6 L/min, p Z 0.23), or other lung function measures. There was no difference between treatment groups in the 6-min walk test, MMRC dyspnoea index, BODE index and CCQ scores. Plasma concentrations indicated that patients were exposed to AZD4818 as expected. AZD4818 was well tolerated: 27 treatment-related adverse events (13 with AZD4818, 14 with placebo), 2 serious adverse events (both AZD4818: exacerbation [considered not treatment-related] and deep vein thrombosis [considered treatment-related]) and 11 discontinuations (7 with AZD4818). Conclusions: Inhaled AZD4818 was well tolerated at 300 mg twice daily for 4 weeks in patients with COPD; however, there was no indication of a beneficial treatment effect despite exposure as expected. These findings in COPD are in line with other studies reporting a lack of clinical efficacy with CCR1 antagonists in other therapy areas. ª (H.A. Kerstjens). a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / r m e d Respiratory Medicine (2010) 104, 1297e1303 0954-6111/$ -see front matter ª
Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder characterised by increasing airflow limitation that is not fully reversible. Current treatments (bronchodilators and anti-inflammatory agents) to some degree relieve symptoms, decrease airflow limitation, and reduce exacerbation frequency but are unable to alter the progression of the disease.
The disease is driven by an inflammatory process accompanied by small airway changes, destruction of lung parenchyma, loss of lung elasticity and enlargement of air spaces. As such, the inflammatory component of COPD may be a target for disease modification. A key element of the inflammatory component of COPD involves the infiltration of lung tissue by inflammatory cells including neutrophils, monocytes and macrophages. These cells are dependent, in part, on the function of the CCR1 chemokine receptor for recruitment and activation in lung tissue. 1e3 We report here the results of a 4-week study designed to evaluate the tolerability and efficacy of inhaled AZD4818, an inhaled CCR1 chemokine receptor antagonist, in patients with moderate to severe COPD.
Methods
This was a phase IIa, 4-week, double-blind, placebocontrolled, randomised, parallel-group study (NCT00629239) of inhaled AZD4818 in patients with moderate to severe COPD conducted across 11 sites in Northern and Western Europe (Fig. 1 ).
Patients
Patients who were current or ex-smokers with at least 10 pack years of smoking, aged !40 years with a confirmed diagnosis of COPD and a symptom duration >12 months were eligible for inclusion in the current study. In addition, patients were required to have a post-bronchodilator forced expiratory volume in 1 second (FEV 1 ) of 40e80% of the predicted normal value and a post-bronchodilator FEV 1 /forced vital capacity (FVC) <70%, daily breathlessness score !1 on at least half of the run-in period and a history of short acting b 2 -agonist or anticholinergic use as rescue medication.
Individuals with a COPD exacerbation within the 30 days prior to study commencement (including use of an oral or systemic glucocorticosteroid), a requirement for regular oxygen therapy, current respiratory tract disorders other than COPD, clinical suspicion of tuberculosis, history of cardiac disorders, malignancy within the past 5 years, or alcohol or drug abuse were not eligible to take part. Additional exclusion criteria included a disease history suggesting impaired immune function and known or suspected hypersensitivity to the study therapy or excipients (e.g. benzoate, lactose).
Upon enrolment, patients' ordinary COPD medication was withdrawn and patients undertook a 2-week wash-out period prior to randomisation. Terbutaline as rescue medication, ipratropium bromide as maintenance treatment, and nasal and dermal glucocorticosteroids were allowed. Prohibited medication included oral, inhaled or systemic glucocorticosteroids, b 2 -agonists other than terbutaline, anticholinergics other than ipratropium bromide, leukotriene antagonists, non-selective b-blockers, medication that prolongs the QT/QTc interval other than inhaled b 2 -agonists, medication containing ephedrine, mucolytics and theophyline.
Study treatments
Patients received either AZD4818 300 mg (two inhalations of 150 mg/dose) as a dry powder for inhalation via Turbuhaler Ò twice daily, or matching placebo. Patients were also permitted terbutaline (Bricanyl Ò Turbuhaler Ò ) (0.5 mg/ dose) as needed and ipratropium bromide as maintenance treatment throughout the study although neither were to be used within 6 and 8 h, respectively, prior to a study visit.
Study endpoints
The primary objective of the study was to investigate the tolerability and safety of inhaled AZD4818 in COPD patients by assessment of the incidence and severity of adverse events, electrocardiograph (ECG), vital signs and laboratory assessments (clinical chemistry, haematology and urinalysis). Adverse events were scored by the investigators while still blinded as related with reasonable possibility or not to the investigational drug.
The secondary objective of the study was to evaluate the effects of inhaled AZD4818 on lung function among COPD patients. Functional assessments included FEV 1 , FVC, mean forced expiratory flow between 25% and 75% of the FVC (FEF 25e75% ), vital capacity (VC), inspiratory capacity (IC) and peak expiratory flow (PEF).
Functional capacity was determined using the 6-min walk test (6MWT); BODE index score (a composite score of body mass index, airway obstruction as assessed by FEV 1 , dyspnoea [as assessed by the Modified Medical Research Council (MMRC) dyspnoea scale] and exercise capacity (6MWT), total range 0e10) and Borg scale during exercise (an assessment of dyspnoea and fatigue, range 0e10) were also evaluated. Health status was assessed with the Clinical COPD Questionnaire 4 (CCQ, range 0e6), COPD symptoms (breathlessness, cough, chest tightness and night-time awakenings, range 0e7), diary rescue medication use. Additional laboratory evaluations included blood cells and soluble plasma inflammatory markers and plasma concentrations of AZD4818. Assessment of serum biomarker levels was performed every 2 weeks from randomisation using a multiplex analysis kit.
Statistical analysis
Descriptive statistics were used to express safety data with adverse event data presented in terms of frequencies.
Other data were analysed using an analysis of variance model with treatment and country as factors and baseline, when relevant, as covariate. Assessment of effects on all laboratory variables was based on the change from baseline (last measurement during the run-in period) to end-oftreatment (the last measurement during the treatment period). For efficacy data, p-values and confidence limits were also generated but were considered to be exploratory.
Results
In total, 65 patients were eligible for inclusion and were randomised to study treatment (AZD4818 n Z 33, placebo n Z 32). Patient flow and baseline characteristics are summarized in Fig. 1 and Table 1 .
Safety
The majority of patients in both treatment arms experienced at least one adverse event during the study (AZD4818 n Z 22 [67%], placebo n Z 27 [84%]); most were mild to moderate in intensity ( Table 2 ). There were no deaths recorded.
A total of 27 adverse events were regarded by the study investigators as possibly related to study treatment.
Two serious adverse events were recorded, both in the AZD4818 treatment arm. These included one case of COPD exacerbation for which the patient required hospitalisation but was not considered related to study treatment by the investigator, and one case of deep vein thrombosis that was considered possibly related to study treatment by the investigator.
Eleven patients withdrew from the study due to an adverse event, 7 (21%) in the AZD4818 group and 4 (13%) in the placebo group.
There were no clinically relevant changes in vital signs, ECG or safety laboratory variables for either group during the study.
Efficacy
There were no statistically significant differences between treatment groups with respect to any of the lung function assessments, functional capacity, modified Medical Research Council Dyspnoea Index, BODE index, Clinical COPD Questionnaire scores, diary card symptoms or rescue medication use ( Table 3 , Fig. 2 ). While change in morning PEF (diary card data) did not differ significantly between the treatment groups, change in evening PEF favoured placebo at the endpoint.
Biomarker measurements
No clinically relevant differences between the two treatment groups were noted in the mean change from baseline in blood cells, including white cell counts and differentials, or soluble mediators (see Supplementary Fig. S1 ).
Pharmacokinetics
All patients receiving inhaled AZD4818 had detectable levels of the drug in their blood samples. The plasma concentration profiles for individual patients indicated that patients were exposed to AZD4818 as expected (see Supplementary Fig. S2 ).
Discussion
AZD4818 at a dose of 300 mg twice daily via Turbuhaler Ò was well tolerated over a 4-week treatment period in COPD patients. However, there was no indication of a beneficial treatment effect of inhaled AZD4818 in terms of clinical efficacy or changes in the number of inflammatory cells in the blood or in other blood-based biomarkers of inflammation. Plasma concentrations indicated that patients were exposed as predicted and well above (70 times) the estimated therapeutic dose in man of a lung deposited dose of 5 mg, which was based on preclinical data from an LPS challenge model in rats. 5, 6 During the development of AZD4818, in vitro and in vivo data were encouraging. In vitro, AZD4818 inhibited the binding of the CCR1 ligand MIP-1a to human, rat, mouse and dog CCR1 receptors in a concentration-dependent manner. 6 Moreover, AZD4818 inhibited chemotaxia of human monocytes to MIP-1a in a concentration-dependent manner. 6 In vivo studies in rats were also encouraging with a significant reduction of neutrophil influx and TNF-a levels on bronchoalveolar lavage (BAL) following intratracheal administration of AZD4818 (1 mg/kg) prior to LPS challenge. 6 In an animal LPS model, a dose-dependent reduction of leukocyte infiltration in BAL fluid was observed following acute delivery of inhaled nebulised AZD4818 (0.3e26 mg/kg) prior to LPS challenge. 5 In an acute 5-day smoke-exposure model in mice, inhaled nebulised AZ11880492 (a structurally similar chloro-analogue of AZD4818) caused a dose-dependent inhibition of neutrophil influx into BAL of the cigarette smoking mice (5 days model) at lung deposited doses 0.3 mg/kg (0.604 nmol/kg) body weight (49% inhibition of neutrophil influx), 4.8 mg/kg (9.66 nmol/kg) (71% inhibition) and 52 mg/kg (105 nmol/kg) (76% inhibition). 6 In a chronic LPS animal model, inhaled nebulised AZD4818 (0.01 mg/mL [19.2 mM] and 1 mg/ml [1920 mM]) once daily for 5 days per week for a period of 4 or 8 weeks significantly reduced infiltrating BAL macrophage cell numbers in the 4-week as well as the 8-week experiments. 6 One possible explanation for the generally disappointing results in humans for CCR1 antagonists may be the variable cross-species reactivity of these agents. 7e9 Indeed, there is some evidence that CCR1 expression/functionality differs between human and rodent neutrophils. For example, a study with the CCR1 ligand MIP-1a revealed fundamental differences in an animal model of respiratory disease in terms of the mechanism of leukocyte priming. 10 Such findings would indicate that current in vivo animal models may not be sufficiently reflective of equivalent human CCR1-mediated processes to evaluate the action and efficacy of CCR1 antagonists in humans. Human transgenic mouse models may prove useful in this setting to identify more potent CCR1-targeted agents and to define their potential clinical profile. 11 Other possible biological explanations for the poor translation of efficacy results from animal models to humans may include the dosing route (oral versus inhaled) and redundancy of CCR1, as CCR1 may not in fact be a critical chemokine in humans. 8 For CCR1, it is possible that local delivery of an antagonist compound directly to the lung tissue in humans might fail to inhibit the chemotactic gradient that facilitates the infiltration of inflammatory cells. Thus, while an oral chemokine receptor antagonist, such as AZD8309, 12 will act to reduce inflammatory cell infiltration in humans, an inhaled chemokine receptor antagonist may not.
The choice of efficacy variables (lung function and symptom control) for the current study may also have contributed to the failure to demonstrate any benefit for active treatment. The clinical parameters chosen are fine for detection and evaluation of bronchodilators but might be limited in their detection of novel compounds. Sputum BMI e body mass index; GCS e glucocorticosteroid; FEV 1 e forced expiratory volume in 1 s post-br e post-bronchodilator; Pred e predicted normal value; VC e vital capacity. a Note that one of the inclusion criteria was COPD symptoms for at least 1 year; the symptoms had been present for at least 1 year for all patients but not necessarily the diagnosis of COPD. induction could have been performed as part of the study in order to come closer to the target organ, but for a multicentre study feasibility aspects also need to be considered and for this reason it was not included. The duration of the current study (4 weeks) was possibly too short to detect any disease-modifying effects of AZD4818, such as an effect on lower airway inflammation. Indeed, the study was not adequately powered to detect any such disease-modifying properties. The study was primarily designed to evaluate safety of the drug, however, based on the efficacy in preclinical studies it was anticipated that a positive efficacy signal would be detected in trends rather than true significant changes over time. The absence of any clinically relevant changes in haematological markers of inflammation (blood cell counts or inflammatory biomarkers) compared with placebo in the current study is in contrast (for blood cell counts) with a previous (unpublished) study with AZD4818 (see Supplementary information). The possibility of chronic effects on sputum levels or the profile of inflammatory cells in the current study cannot be ruled out as they were not specifically evaluated. Moreover, despite a prior observation of changes in the sputum inflammatory cell profile following acute AZD4818 exposure in a rat LPS challenge model, 5 repeated dosing of AZD4818 in a double-blind, randomised, placebo-controlled, crossover study in healthy males (aged 18e45 years) found that inhaled AZD4818 at 800 mg twice daily via Turbuhaler for 7 days did not reduce the numbers of neutrophils, monocytes and other white blood cells or the levels of inflammatory markers in induced sputum and blood after LPS challenge. 6 The current study evaluated the effect by AZD4818 as monotherapy compared with placebo. However, CCR1 is one of several chemokine receptors involved in neutrophilic inflammation and blocking only one receptor may be insufficient for to have sufficient biological effect. Hence, it cannot be ruled out that additive or synergistic effects might be achieved by combining the drug with other mediator antagonists. Future research should explore the potential for combined targeting of multiple chemokine receptors for the treatment of diseases with an inflammatory component.
In conclusion, inhaled AZD4818 was well tolerated at 300 mg twice daily for 4 weeks in patients with COPD; however, there was no indication of a beneficial treatment effect despite exposure as expected. These findings in COPD are consistent with other studies that have reported a lack of clinical efficacy with CCR1 antagonists, such as BX471 for multiple sclerosis 13, 14 and CP-481715 for rheumatoid arthritis, 15 in humans despite promising results in animal models. 16e18
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